# Bonk, Inc.: financial statements, quarterly

BNKK · Nasdaq · CIK 1760903 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bnkk.md) · [Financials](/companies/bnkk/financials.md) · [Filings](/companies/bnkk/filings.md) · [Insiders](/companies/bnkk/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bnkk/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001493152-24-045990.md) | [0.1 d](/filings/0001641172-25-001259.md) | [0.2](/filings/0001641172-25-010835.md) | [0.7](/filings/0001641172-25-024184.md) | [0.1](/filings/0001493152-25-024307.md) | [0.2 d](/filings/0001493152-26-014015.md) | [0.0](/filings/0001493152-26-022743.md) | [0.0](/filings/0001493152-26-038241.md) | [1.5](/filings/0001493152-25-024307.md) | [0.5 d](/filings/0001493152-26-014015.md) | [0.8](/filings/0001493152-26-022743.md) | [0.8](/filings/0001493152-26-038241.md) |
| Cost of revenue | $m | [0.0](/filings/0001493152-24-045990.md) | [0.2 d](/filings/0001641172-25-001259.md) | [2.4](/filings/0001641172-25-010835.md) | [0.5](/filings/0001641172-25-024184.md) | [0.4](/filings/0001493152-25-024307.md) | [0.6 d](/filings/0001493152-26-014015.md) | [0.0](/filings/0001493152-26-022743.md) | [0.0](/filings/0001493152-26-038241.md) | [1.5](/filings/0001493152-25-024307.md) | [1.2 d](/filings/0001493152-26-014015.md) | [0.7](/filings/0001493152-26-022743.md) | [0.8](/filings/0001493152-26-038241.md) |
| Gross profit | $m | [(0.0)](/filings/0001493152-24-045990.md) | [(0.0) d](/filings/0001641172-25-001259.md) | [(2.2)](/filings/0001641172-25-010835.md) | [0.2](/filings/0001641172-25-024184.md) | [(0.3)](/filings/0001493152-25-024307.md) | [(0.4) d](/filings/0001493152-26-014015.md) | [0.0](/filings/0001493152-26-022743.md) | [0.0](/filings/0001493152-26-038241.md) | [0.5](/filings/0001493152-25-024307.md) | [0.7 d](/filings/0001493152-26-014015.md) | [3.6](/filings/0001493152-26-022743.md) | [0.4](/filings/0001493152-26-038241.md) |
| Research and development | $m | [0.1 d](/filings/0001493152-24-045990.md) | [0.0 d](/filings/0001641172-25-001259.md) | [0.1](/filings/0001641172-25-010835.md) | [0.1](/filings/0001641172-25-024184.md) | [0.0](/filings/0001493152-25-024307.md) | [(0.2) d](/filings/0001493152-26-014015.md) | [0.0](/filings/0001641172-25-010835.md) | [0.0](/filings/0001641172-25-024184.md) | [0.0](/filings/0001493152-25-024307.md) | [0.0 d](/filings/0001493152-26-038241.md) | [0.0](/filings/0001493152-26-022743.md) | [0.0 d](/filings/0001493152-26-038241.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.1](/filings/0001641172-25-010835.md) | [0.1](/filings/0001641172-25-024184.md) | [0.1](/filings/0001493152-25-024307.md) | not reported | not reported | not reported |
| Net income | $m | [(7.7)](/filings/0001493152-24-045990.md) | [(5.7) d](/filings/0001641172-25-001259.md) | [(15.7)](/filings/0001493152-25-024307.md) | [(8.3)](/filings/0001493152-25-024307.md) | [(11.9)](/filings/0001493152-25-024307.md) | [(13.5) d](/filings/0001493152-26-014015.md) | [(5.3)](/filings/0001493152-26-038241.md) | [13.4](/filings/0001493152-26-038241.md) | [(33.6)](/filings/0001493152-25-024307.md) | [(42.7) d](/filings/0001493152-26-014015.md) | [(1.8)](/filings/0001493152-26-038241.md) | [(6.1)](/filings/0001493152-26-038241.md) |
| Diluted EPS | $ per share | [(0.26)](/filings/0001493152-24-045990.md) | not reported | [(0.33)](/filings/0001641172-25-010835.md) | [(0.16)](/filings/0001641172-25-024184.md) | [(0.21)](/filings/0001493152-24-045990.md) | not reported | [(0.08)](/filings/0001641172-25-010835.md) | [3.12](/filings/0001493152-26-038241.md) | not reported | not reported | not reported | [(0.76)](/filings/0001493152-26-038241.md) |
| Basic EPS | $ per share | [(0.26)](/filings/0001493152-24-045990.md) | not reported | [(0.33)](/filings/0001641172-25-010835.md) | [(0.16)](/filings/0001641172-25-024184.md) | [(0.21)](/filings/0001493152-25-024307.md) | not reported | [(2.69)](/filings/0001493152-26-022743.md) | [5.63](/filings/0001493152-26-038241.md) | [(0.22)](/filings/0001493152-25-024307.md) | not reported | [(0.23)](/filings/0001493152-26-022743.md) | [(0.76)](/filings/0001493152-26-038241.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.4](/filings/0001493152-24-001400.md) | [3.8](/filings/0001641172-25-001259.md) | [2.0](/filings/0001493152-24-019873.md) | [3.2](/filings/0001493152-24-032325.md) | [1.4](/filings/0001493152-24-045990.md) | [0.3](/filings/0001493152-26-014015.md) | [0.3](/filings/0001641172-25-010835.md) | [0.5](/filings/0001641172-25-024184.md) | [9.0](/filings/0001493152-25-024307.md) | [2.3](/filings/0001493152-26-038241.md) | [0.7](/filings/0001493152-26-022743.md) | [0.2](/filings/0001493152-26-038241.md) |
| Current assets | $m | [8.2](/filings/0001493152-24-001400.md) | [7.7](/filings/0001641172-25-001259.md) | [4.3](/filings/0001493152-24-019873.md) | [5.9](/filings/0001493152-24-032325.md) | [3.5](/filings/0001493152-24-045990.md) | [2.6](/filings/0001493152-26-014015.md) | [4.0](/filings/0001641172-25-010835.md) | [21.9](/filings/0001641172-25-024184.md) | [58.5](/filings/0001493152-25-024307.md) | [6.0](/filings/0001493152-26-038241.md) | [6.5](/filings/0001493152-26-022743.md) | [4.3](/filings/0001493152-26-038241.md) |
| Total assets | $m | [11.3](/filings/0001493152-24-001400.md) | [12.7](/filings/0001641172-25-001259.md) | [9.2](/filings/0001493152-24-019873.md) | [10.7](/filings/0001493152-24-032325.md) | [8.4](/filings/0001493152-24-045990.md) | [7.3](/filings/0001493152-26-014015.md) | [8.7](/filings/0001641172-25-010835.md) | [42.1](/filings/0001641172-25-024184.md) | [81.0](/filings/0001493152-25-024307.md) | [41.0](/filings/0001493152-26-038241.md) | [38.4](/filings/0001493152-26-022743.md) | [31.6](/filings/0001493152-26-038241.md) |
| Current liabilities | $m | [4.3](/filings/0001493152-24-001400.md) | [3.6](/filings/0001641172-25-001259.md) | [3.4](/filings/0001493152-24-019873.md) | [3.4](/filings/0001493152-24-032325.md) | [1.8](/filings/0001493152-24-045990.md) | [9.4](/filings/0001493152-26-014015.md) | [9.2](/filings/0001641172-25-010835.md) | [18.9](/filings/0001641172-25-024184.md) | [5.5](/filings/0001493152-25-024307.md) | [6.0](/filings/0001493152-26-038241.md) | [5.1](/filings/0001493152-26-022743.md) | [4.1](/filings/0001493152-26-038241.md) |
| Total liabilities | $m | [4.6](/filings/0001493152-24-001400.md) | [3.9](/filings/0001641172-25-001259.md) | [3.6](/filings/0001493152-24-019873.md) | [4.2](/filings/0001493152-24-032325.md) | [2.0](/filings/0001493152-24-045990.md) | [9.5](/filings/0001493152-26-014015.md) | [9.2](/filings/0001641172-25-010835.md) | [19.0](/filings/0001641172-25-024184.md) | [5.5](/filings/0001493152-25-024307.md) | [6.0](/filings/0001493152-26-038241.md) | [5.1](/filings/0001493152-26-022743.md) | [4.1](/filings/0001493152-26-038241.md) |
| Shareholders' equity | $m | [6.7](/filings/0001493152-24-045990.md) | [8.8](/filings/0001493152-26-014015.md) | [5.6](/filings/0001493152-25-024307.md) | [6.5](/filings/0001493152-25-024307.md) | [6.4](/filings/0001493152-25-024307.md) | [(2.2)](/filings/0001493152-26-038241.md) | [(0.5)](/filings/0001493152-26-038241.md) | [23.1](/filings/0001493152-26-038241.md) | [75.5](/filings/0001493152-25-024307.md) | [35.0](/filings/0001493152-26-038241.md) | [33.3](/filings/0001493152-26-038241.md) | [27.5](/filings/0001493152-26-038241.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(2.9) d](/filings/0001493152-23-041666.md) | [(5.5) d](/filings/0001493152-24-045990.md) | [(6.4)](/filings/0001641172-25-010835.md) | [(5.7) d](/filings/0001641172-25-024184.md) | [(5.1) d](/filings/0001493152-25-024307.md) | [(0.8) d](/filings/0001641172-25-010835.md) | [(4.6)](/filings/0001493152-26-022743.md) | [(0.7) d](/filings/0001493152-26-038241.md) | [(13.7) d](/filings/0001493152-25-024307.md) | [(6.2) d](/filings/0001493152-26-038241.md) | [(1.9)](/filings/0001493152-26-022743.md) | [(2.2) d](/filings/0001493152-26-038241.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities, us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
- Capital expenditure: not reported
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [23.1](/filings/0001493152-23-016631.md) | [21.9](/filings/0001493152-23-028423.md) | [21.5](/filings/0001493152-24-001400.md) | [25.6](/filings/0001493152-24-019873.md) | [25.6](/filings/0001493152-24-032325.md) | [29.8](/filings/0001493152-24-045990.md) | [47.4](/filings/0001641172-25-010835.md) | [51.7](/filings/0001641172-25-024184.md) | [55.9](/filings/0001493152-24-045990.md) | [69.3](/filings/0001641172-25-010835.md) | [4.3](/filings/0001493152-26-038241.md) | [8.0](/filings/0001493152-26-038241.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 8,000,940 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-038241.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.